Radiopharma developer Aktis Oncology priced an upsized IPO at $18 a share, raising $318 million in gross proceeds, and saw its stock surge about 25% in the debut trading session. The combination of strong pricing and early aftermarket performance is being read as a positive signal for other biopharma IPOs this year. Company communications stressed proceeds will fund ongoing clinical programs and platform expansion.